MarketPulse

cash runway

18 articles
The Motley FoolThe Motley Fool··Sarah Sidlow

Maze Therapeutics CSBO Sells $190K in Stock Despite Strong Trial Data

Maze Therapeutics CSBO Atul Dandekar sold 7,500 shares for $190,000 under a pre-planned trading agreement, concurrent with positive phase 2 trial results.
MAZEclinical-stage biotechprecision medicine
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

TScan Therapeutics Posts $28.7M Q1 Loss as Pipeline Advances Toward Phase 3

TScan Therapeutics reports $28.7M Q1 loss, $1.0M revenue; $128.1M cash funds operations to H2 2027 amid Phase 3 pipeline advancement.
TCRXclinical developmentPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Eyepoint, Inc.

EyePoint Faces Revenue Collapse as DURAVYU AMD Trials Advance Into 2026

EyePoint reports 97% revenue decline to $0.7M in Q1 2026 amid $84.8M net loss, but maintains $223M cash runway through Q4 2027 as DURAVYU Phase 3 trials advance.
EYPTregulatory approvalretinal diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Fulcrum Therapeutics Advances Sickle Cell Program With Positive Data, Eyes 2029 Runway

Fulcrum Therapeutics reports positive pociredir data in sickle cell disease, plans registration trial in H2 2026, maintains $333.3M cash runway through 2029.
FULCclinical trialFDA
Investing.comInvesting.com··Vishal Jadaun

IonQ Surges on DARPA Deal as Quantum Computing Edges Toward Commercial Reality

IonQ stock surges 18.4% on DARPA contract win, validating quantum computing progress amid $2.39B cash runway and 428.5% YoY revenue growth.
MSFTIONQIONQ.WSoperating lossesquantum computing
The Motley FoolThe Motley Fool··Will Healy

IonQ's Quantum Promise Dims: Why Dollar-Cost Averaging May Be Risky

IonQ faces widening losses despite revenue growth, trades at 61x sales, and confronts intense competition from tech giants in quantum computing sector.
GOOGGOOGLIONQIONQ.WSIBMquantum computingvaluation concerns
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Opus Genetics Secures $155M Non-Dilutive Funding to Accelerate Retinal Gene Therapy Pipeline

Opus Genetics secures $155M non-dilutive funding from Oberland Capital, extending cash runway through 2029 and accelerating gene therapy development for inherited retinal diseases.
IRDclinical developmentgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Werewolf Therapeutics Explores Strategic Alternatives as Cash Runway Extends to Late 2026

Werewolf Therapeutics seeks strategic alternatives including potential sale or merger. Company reports improved 2025 financials, reduced losses, and $57.1M cash reserves.
HOWLfinancial resultsbiopharmaceutical
The Motley FoolThe Motley Fool··Eric Volkman

Celcuity Beats Loss Expectations, Stock Surges on Strengthened Cash Position

Celcuity stock rises over 4% after beating loss expectations and securing $166M cash position, with phase 3 trial results anticipated in Q2.
CELCearningsbiotech
BenzingaBenzinga··Globe Newswire

Reviva Pharmaceuticals Closes $10M Offering to Fund Schizophrenia Drug Trial

Reviva Pharmaceuticals closed a $10M public offering at $1.50/share to fund its RECOVER-2 Phase 3 schizophrenia trial, maintaining $23M cash through Q1 2027.
RVPHwarrantspublic offering
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling $PRAX Soars 700% as Top Fund Trims Position Yet Doubles Down

Cormorant Asset Management sold $PRAX shares for $9.3M in Q4, yet position surged $227M in value. Stock remains fund's largest holding at $280M.
EYPTPRAXABVXFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Molecular Partners Posts $61.7M Loss but Funds Pipeline Through 2028

Molecular Partners reports CHF 61.7M net loss but maintains CHF 93.1M cash runway through 2028, advancing Radio-DARPin and immuno-oncology pipeline programs.
MOLNfinancial resultsclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Proqr Therapeutics N.V.

ProQR Advances Gene Therapy Pipeline as Cash Runway Extends to Mid-2027

ProQR reported €92.4M cash, advanced lead program AX-0810 into Phase 1, and achieved $4.5M in Eli Lilly milestones, projecting runway into mid-2027.
LLYPRQRPhase 1 clinical trialbiotech pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Seres Therapeutics, Inc.

Seres Therapeutics Swings to $5.7M Profit on Nestlé VOWST Sale, Eyes 2026 Clinical Data

Seres Therapeutics swung to $5.7M 2025 profit from $125.8M loss, boosted by Nestlé VOWST sale, with $45.8M cash funding ops through Q3 2026.
MCRBclinical trialinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lyell Immunopharma Secures $50M Funding Tranche on Clinical Progress

Lyell Immunopharma closes $50M funding tranche, advances ronde-cel in pivotal lymphoma trial, appoints new CFO with extended cash runway through Q2 2027.
LYELCAR T-cell therapycash runway
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Boundless Bio Extends Cash Runway to Mid-2028 Amid BBI-940 Clinical Expansion

Boundless Bio reported $107.6M cash, narrowed 2025 net losses to $58.2M, and is advancing lead breast cancer candidate BBI-940 through Phase 2 trials.
BOLDbreast cancercash runway
GlobeNewswire Inc.GlobeNewswire Inc.··Jade Biosciences, Inc.

Jade Biosciences Posts $127.4M Loss, Eyes 2028 Cash Runway With Pipeline Catalysts

Jade Biosciences reports $127.4M full-year loss, maintains $336.2M cash runway through mid-2028 with pipeline data catalysts starting Q2 2026.
JBIOmonoclonal antibodyclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Strengthens Balance Sheet With $172.5M Offering; Eyes Mid-2027 Cash Runway

Inventiva raises $172.5M, strengthening balance sheet to €230.9M in liquidity. Clinical-stage biotech projects cash runway through mid-2027 to advance MASH treatment program.
IVApublic offeringclinical-stage biopharmaceutical